In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Li Hu *National Clinical Research Center for Metabolic Diseases and the Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Jie Wen *Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, China.
Hairong LuoNational Clinical Research Center for Metabolic Diseases and the Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Dongqing YinDepartment of Cell Systems & Anatomy, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Juanhong LiuNational Clinical Research Center for Metabolic Diseases and the Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.ORCID http://orcid.org/0000-0001-6697-421X Yan YangNational Clinical Research Center for Metabolic Diseases and the Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Jingjing ZhangNational Clinical Research Center for Metabolic Diseases and the Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.ORCID http://orcid.org/0000-0002-9155-8979 Cynthia JuDepartment of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1640-7169 Alan FrazerDepartment of Pharmacology, University of Texas Health San Antonio, San Antonio, TX, USA.
Feng LiuNational Clinical Research Center for Metabolic Diseases and the Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. liuf001@csu.edu.cn.ORCID http://orcid.org/0000-0002-5098-1711 Funding
Adiponectin signaling and macrophage functionR01DK134637 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lily Q Dong, ELIZABETH Ann LEADBETTER · 2023 to 2026
$2.1MRegulation of Mitochondrial Biogenesis and Function by DsbA-L in the LiverR01DK114479 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FRAZER, ALAN · 2018 to 2021
$1.4MAmerican Diabetes Association (ADA) 1-19-IBS-147National Natural Science Foundation of China (National Science Foundation of China) 82330025National Natural Science Foundation of China (National Science Foundation of China) 82370807National Natural Science Foundation of China (National Science Foundation of China) 82401013NIDDK NIH HHS R01 DK114479NIDDK NIH HHS R01 DK134637U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) DK114479U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) DK134637
6 · The paper itselfAbstract
Whereas mitochondrial dysfunction is implicated in metabolic dysfunction-associated steatohepatitis (MASH), the precise underlying mechanisms remain obscure. Here, we identify the Sirtuin 3 (SIRT3)-Disulfide-bond-A oxidoreductase-like protein (DsbA-L)-Mitochondrial Transcription Factor A (TFAM) axis as a crucial suppressor for mitochondrial stress-induced cyclic GMP-AMP synthase (cGAS) activation in hepatocytes, thereby alleviating MASH in mice. SIRT3 facilitates the deacetylation of DsbA-L at lysine residues (Lys
Indexed as
DNA-Binding ProteinsFatty LiverMitochondrial ProteinsNucleotidyltransferasesSirtuin 3Transcription FactorsAnimalscGAS-STING Signaling PathwayCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDNA, MitochondrialHepatocytesHigh Mobility Group ProteinsHumansLiverMaleMicecGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDNA-Binding ProteinsDNA, MitochondrialHigh Mobility Group ProteinsMitochondrial ProteinsNucleotidyltransferasesSirt3 protein, mouseSirtuin 3Tfam protein, mouseTranscription Factors
Identifiers
PMID42082480
PMCPMC13478530
What OpenQuestion holds
Textmetadata
Read underepoch 390